LISA J SIMMONS MD NPI 1790773737

NPI Details

Lisa J Simmons, MD is a hematology and oncology internal medicine in Fredericksburg, VA with 27 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Lisa J Simmons, MD NPI is 1790773737. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF MISSOURI, COLUMBIA SCHOOL OF MEDICINE
Graduation Year:1999

The provider's business location address is:

4501 EMPIRE CT
FREDERICKSBURG, VA
ZIP 22408-949
Phone: (540) 371-0079
Fax: (540) 656-2769

The NPI 1790773737 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Magnesium level (HCPCS:83735)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, rituximab-arrx, biosimilar, (riabni), 10 mg (HCPCS:Q5123)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Iron binding capacity (HCPCS:83550)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Phosphate level (HCPCS:84100)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Urinalysis, manual test (HCPCS:81002)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Uric acid level, blood (HCPCS:84550)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Unclassified drugs (HCPCS:J3490)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Collection of blood sample from implanted device (HCPCS:36591)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Prealbumin (protein) level (HCPCS:84134)
• Vitamin d-3 level (HCPCS:82306)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Drawing of blood for a medical problem (HCPCS:99195)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report (HCPCS:93000)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Adm sarscov2 100mcg/0.5ml3rd (HCPCS:0013A)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Stool analysis for blood, by peroxidase activity (HCPCS:82272)
• Injection of drug or substance into vein (HCPCS:96374)

The enumeration date for this NPI number is 10/13/2005 and was last updated on 8/19/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.